Precision radiation targets prostate tumors with MRI guidance
NCT ID NCT06542757
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new way to deliver radiation for intermediate-risk prostate cancer. Using an MRI machine that also delivers radiation, doctors can give a higher dose to the main tumor while lowering the dose to the rest of the prostate. The goal is to improve tumor control and reduce side effects. About 91 participants will be followed for two years to see if the tumor is gone on biopsy and to track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (MR-guided ultra-hypofractionated external beam radiation with a dose boost to the dominant tumor)
What this could lead to
If successful, this approach could offer a more precise and effective radiation treatment for intermediate-risk prostate cancer, potentially reducing side effects and improving tumor control.
What could go wrong
This is a small, early-phase study (91 participants) with no control group, so results may not apply broadly. There are risks of radiation side effects, and the treatment may not improve outcomes over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States